SBTX - Ticker AI Digest

SkinBioTherapeutics PLC 📰 1
Desk Snapshot GO VIP Login
Important AI Risk Notice

Charts, catalyst summaries, AI scores, forecasts and price context are AI-driven and can hallucinate, lag or miss market-changing information.

Not investment advice. Markets can move fast and any trade or allocation decision remains your responsibility.
AI can hallucinate. Summaries, rankings, forecasts and commentary can be wrong, incomplete or misleading.
AI-driven data only. Signals, dates, prices, sentiment and automation outputs may be delayed, estimated or stale.
Always verify externally. Confirm prices, filings, broker notes and trade setup details with independent sources before acting.
Mobile Command Deck
SkinBioTherapeutics PLC in one cleaner mobile flow.
Tap straight into the module you want. No sideways tab hunt, just a clean route into charts, news, Today’s AI, and the deeper desks.
SBTX Data 2025-12-05 Preview Mode
Core Deck
Deep Dive Modules

Digested News

Today's Catalysts (SBTX) 1
SBTX 06:01
SkinBioTherapeutics PLC
Final Results
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
SkinBioTherapeutics PLC, a life science group focused on skin health, reported its full-year results for the 12 months ended 30 June 2025, highlighting continued growth and evolution. Key operational highlights include the completion of Croda studies and the finalization of a commercial agreement, leading to the launch of Zenakine™ (SkinBiotix®) in the global cosmetics industry in April 2025. The company also expanded its AxisBiotix™ product line, signed an exclusive commercial agreement with Superdrug Stores plc, and acquired Bio-Tech Solutions to enhance manufacturing capabilities.
Financial performance showed significant growth, with revenues increasing by 284% to £4.6 million, driven by contributions from AxisBiotix™ direct sales, Dermatonics, Bio-Tech Solutions, and royalty income. Adjusted EBITDA improved to £(0.4) million, and the operating loss narrowed to £1.1 million. Cash and cash equivalents stood at £4.8 million, supported by successful fundraisings.
Strategically, SkinBioTherapeutics strengthened its commercial partnerships, particularly with Croda and Superdrug, and integrated acquisitions to broaden its product portfolio and manufacturing capabilities. The company also made management changes, appointing new executives and board members to support its growth trajectory.
Looking ahead, the company anticipates further growth in FY2026, with market expectations of £6.2 million in revenue and £0.7 million in adjusted EBITDA. The focus will be on expanding the reach of Zenakine™ and AxisBiotix™ products, leveraging the Superdrug partnership, and continuing its consolidation strategy in the skincare market.
**Summary**
SkinBioTherapeutics PLC reported strong FY2025 results, marked by significant revenue growth, strategic partnerships, and acquisitions. The company launched Zenakine™ globally, expanded its AxisBiotix™ line, and secured a major retail deal with Superdrug. Financial improvements and management changes position the company for continued growth in FY2026, with a focus on product expansion and market consolidation.
Here is the HTML table code comparing the financials and debt year on year for SkinBioTherapeutics PLC: td>497%
Financial Metric2024 (£)2025 (£)Change (£)Change (%)
Revenue1,208,6694,638,1473,429,478284%
Gross Profit683,0382,859,2802,176,242319%
Operating Loss(2,905,132)(1,123,135)1,782,00761%
Cash and Cash Equivalents800,9044,779,4333,978,529
Total Debt (Borrowings + Convertible Loan)740,000600,000(140,000)(19%)
**Notes:** * Total Debt is calculated as the sum of Borrowings and Convertible Loan. * The convertible loan was fully converted into equity in 2025, hence the decrease in total debt. * The significant increase in revenue and gross profit is attributed to the full year trading of Dermatonics, nine months of sales from Bio-Tech Solutions, and royalty income from Zenakine™. * The improvement in operating loss is due to the increased revenue and synergies from acquisitions. * The substantial increase in cash and cash equivalents is a result of successful fund raisings and cash inflows from acquired companies. This table provides a concise comparison of key financial metrics and debt levels between 2024 and 2025 for SkinBioTherapeutics PLC.
AI 0
No items for this category on selected date.
Acquisitions 0
No items for this category on selected date.
Agreement 0
No items for this category on selected date.
Approvals 0
No items for this category on selected date.
Authorisation 0
No items for this category on selected date.
Awards 0
No items for this category on selected date.
BTC 0
No items for this category on selected date.
Blockchain 0
No items for this category on selected date.
Breakthrough 0
No items for this category on selected date.
BuyBack 0
No items for this category on selected date.
Cancellations 0
No items for this category on selected date.
CashOffer 0
No items for this category on selected date.
Collaborate 0
No items for this category on selected date.
ContractWin 0
No items for this category on selected date.
Covid-19 0
No items for this category on selected date.
Deals 0
No items for this category on selected date.
Diamond 0
No items for this category on selected date.
DirectorDealing 0
No items for this category on selected date.
Discovery 0
No items for this category on selected date.
Exceeded 0
No items for this category on selected date.
FCA 0
No items for this category on selected date.
FDA 0
No items for this category on selected date.
Grants 0
No items for this category on selected date.
InvestmentPlan 0
No items for this category on selected date.
JV 0
No items for this category on selected date.
Launch 0
No items for this category on selected date.
Litigation 0
No items for this category on selected date.
NewContract 0
No items for this category on selected date.
Offers 0
No items for this category on selected date.
Offtake 0
No items for this category on selected date.
Orders 0
No items for this category on selected date.
Partner 0
No items for this category on selected date.
Patents 0
No items for this category on selected date.
Placing 0
No items for this category on selected date.
Positive 0
No items for this category on selected date.
Proposals 0
No items for this category on selected date.
Reports 0
No items for this category on selected date.
Results 1
SBTX 06:01
SkinBioTherapeutics PLC
Final Results
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
SkinBioTherapeutics PLC, a life science group focused on skin health, reported its full-year results for the 12 months ended 30 June 2025, highlighting continued growth and evolution. Key operational highlights include the completion of Croda studies and the finalization of a commercial agreement, leading to the launch of Zenakine™ (SkinBiotix®) in the global cosmetics industry in April 2025. The company also expanded its AxisBiotix™ product line, signed an exclusive commercial agreement with Superdrug Stores plc, and acquired Bio-Tech Solutions to enhance manufacturing capabilities.
Financial performance showed significant growth, with revenues increasing by 284% to £4.6 million, driven by contributions from AxisBiotix™ direct sales, Dermatonics, Bio-Tech Solutions, and royalty income. Adjusted EBITDA improved to £(0.4) million, and the operating loss narrowed to £1.1 million. Cash and cash equivalents stood at £4.8 million, supported by successful fundraisings.
Strategically, SkinBioTherapeutics strengthened its commercial partnerships, particularly with Croda and Superdrug, and integrated acquisitions to broaden its product portfolio and manufacturing capabilities. The company also made management changes, appointing new executives and board members to support its growth trajectory.
Looking ahead, the company anticipates further growth in FY2026, with market expectations of £6.2 million in revenue and £0.7 million in adjusted EBITDA. The focus will be on expanding the reach of Zenakine™ and AxisBiotix™ products, leveraging the Superdrug partnership, and continuing its consolidation strategy in the skincare market.
**Summary**
SkinBioTherapeutics PLC reported strong FY2025 results, marked by significant revenue growth, strategic partnerships, and acquisitions. The company launched Zenakine™ globally, expanded its AxisBiotix™ line, and secured a major retail deal with Superdrug. Financial improvements and management changes position the company for continued growth in FY2026, with a focus on product expansion and market consolidation.
Here is the HTML table code comparing the financials and debt year on year for SkinBioTherapeutics PLC: td>497%
Financial Metric2024 (£)2025 (£)Change (£)Change (%)
Revenue1,208,6694,638,1473,429,478284%
Gross Profit683,0382,859,2802,176,242319%
Operating Loss(2,905,132)(1,123,135)1,782,00761%
Cash and Cash Equivalents800,9044,779,4333,978,529
Total Debt (Borrowings + Convertible Loan)740,000600,000(140,000)(19%)
**Notes:** * Total Debt is calculated as the sum of Borrowings and Convertible Loan. * The convertible loan was fully converted into equity in 2025, hence the decrease in total debt. * The significant increase in revenue and gross profit is attributed to the full year trading of Dermatonics, nine months of sales from Bio-Tech Solutions, and royalty income from Zenakine™. * The improvement in operating loss is due to the increased revenue and synergies from acquisitions. * The substantial increase in cash and cash equivalents is a result of successful fund raisings and cash inflows from acquired companies. This table provides a concise comparison of key financial metrics and debt levels between 2024 and 2025 for SkinBioTherapeutics PLC.
Significant 0
No items for this category on selected date.
Speculation 0
No items for this category on selected date.
Strategic 0
No items for this category on selected date.
Suspension 0
No items for this category on selected date.
TR1 2
SBTX 06:01
SkinBioTherapeutics PLC
Holding(s) in Company
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
<mark style="background-coloryellow">TR1</mark> Buy
SBTX 06:01
SkinBioTherapeutics PLC
Holding(s) in Company
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
<mark style="background-coloryellow">TR1</mark> Buy
Takeover 0
No items for this category on selected date.
Understanding 0
No items for this category on selected date.
Updates 0
No items for this category on selected date.
Vaccine 0
No items for this category on selected date.
Wins 0
No items for this category on selected date.
Worth 0
No items for this category on selected date.
All Market News (Last 30 Days) 3
SBTX 06:01
SkinBioTherapeutics PLC
Final Results
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
SkinBioTherapeutics PLC, a life science group focused on skin health, reported its full-year results for the 12 months ended 30 June 2025, highlighting continued growth and evolution. Key operational highlights include the completion of Croda studies and the finalization of a commercial agreement, leading to the launch of Zenakine™ (SkinBiotix®) in the global cosmetics industry in April 2025. The company also expanded its AxisBiotix™ product line, signed an exclusive commercial agreement with Superdrug Stores plc, and acquired Bio-Tech Solutions to enhance manufacturing capabilities.
Financial performance showed significant growth, with revenues increasing by 284% to £4.6 million, driven by contributions from AxisBiotix™ direct sales, Dermatonics, Bio-Tech Solutions, and royalty income. Adjusted EBITDA improved to £(0.4) million, and the operating loss narrowed to £1.1 million. Cash and cash equivalents stood at £4.8 million, supported by successful fundraisings.
Strategically, SkinBioTherapeutics strengthened its commercial partnerships, particularly with Croda and Superdrug, and integrated acquisitions to broaden its product portfolio and manufacturing capabilities. The company also made management changes, appointing new executives and board members to support its growth trajectory.
Looking ahead, the company anticipates further growth in FY2026, with market expectations of £6.2 million in revenue and £0.7 million in adjusted EBITDA. The focus will be on expanding the reach of Zenakine™ and AxisBiotix™ products, leveraging the Superdrug partnership, and continuing its consolidation strategy in the skincare market.
**Summary**
SkinBioTherapeutics PLC reported strong FY2025 results, marked by significant revenue growth, strategic partnerships, and acquisitions. The company launched Zenakine™ globally, expanded its AxisBiotix™ line, and secured a major retail deal with Superdrug. Financial improvements and management changes position the company for continued growth in FY2026, with a focus on product expansion and market consolidation.
Here is the HTML table code comparing the financials and debt year on year for SkinBioTherapeutics PLC: td>497%
Financial Metric2024 (£)2025 (£)Change (£)Change (%)
Revenue1,208,6694,638,1473,429,478284%
Gross Profit683,0382,859,2802,176,242319%
Operating Loss(2,905,132)(1,123,135)1,782,00761%
Cash and Cash Equivalents800,9044,779,4333,978,529
Total Debt (Borrowings + Convertible Loan)740,000600,000(140,000)(19%)
**Notes:** * Total Debt is calculated as the sum of Borrowings and Convertible Loan. * The convertible loan was fully converted into equity in 2025, hence the decrease in total debt. * The significant increase in revenue and gross profit is attributed to the full year trading of Dermatonics, nine months of sales from Bio-Tech Solutions, and royalty income from Zenakine™. * The improvement in operating loss is due to the increased revenue and synergies from acquisitions. * The substantial increase in cash and cash equivalents is a result of successful fund raisings and cash inflows from acquired companies. This table provides a concise comparison of key financial metrics and debt levels between 2024 and 2025 for SkinBioTherapeutics PLC.
SBTX 06:01
SkinBioTherapeutics PLC
Holding(s) in Company
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
<mark style="background-coloryellow">TR1</mark> Buy
SBTX 06:01
SkinBioTherapeutics PLC
Holding(s) in Company
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
<mark style="background-coloryellow">TR1</mark> Buy

Today's AI

Today's AI Starts With News

1 live catalyst is opening Today’s AI for SBTX.

Start with the live headline tape first. Today’s AI findings sit next, and the AI Blend stack drops lower once the news context is framed. Financial Forecastist now feeds the blend too.
Live Tape Data 2025-12-05 Blend Lower Down
Read the alert tape first, then open Today’s AI findings. Use AI Expand on any card to open the AI explanation, results tables and financial forecast rows instantly.
1 Today
Front Of Desk
SkinBioTherapeutics PLC has fresh news flow live now, so Today’s AI is leading with the tape before the blended signal stack below.
Single-Ticker Today's AI
SBTX signal theatre built from scored market catalysts, automated AI forecasts, financial forecasting and live trigger logic.

This is the ticker-specific Today’s AI desk for SkinBioTherapeutics PLC. It compresses the live catalyst tape, bullish and bearish scoring, AI price forecasts, financial forecasting and trigger logic into one cockpit so users can judge conviction without hopping across screens.

Subscription Required Bullish vs Bearish Scoring AI + Financial Blend Buy / Sell Trigger Engine Today's AI Findings
Create Account Member Login
Subscriber Unlock
Subscribe to unlock the full SBTX Today’s AI cockpit.

Subscription turns this tab into a live signal desk with today’s news findings at the top, AI plus financial blend comparisons at the bottom, buy and sell trigger logic, and the full findings ledger behind every scored row.

  • AI-scored market headlines with sentiment buckets and buzzword breakdowns.
  • Forecast leaders ranked by projected gain against current market price.
  • Advanced technical scans, AI forecast stacks, and predictive MACD inside the live stock terminal charts.
  • Single-ticker AI Crunch desks with buy or sell trigger logic and full catalyst ledgers.
  • Scored earnings shock board with predicted direction, sector pulse and catalyst narrative.
  • Fast market scan built for event-driven trading, not passive dashboards.
Subscribe to unlock the ticker-specific Today’s AI stack, sentiment gauges, AI blend stage, and the full findings ledger for SBTX on 2025-12-05.

Fundamentals Matrix

Overall Fundamentals
Signal: Pending
Capital Strength
Signal: Pending
Float Liquidity
Signal: Pending
Short Pressure
Signal: Pending
Target Setup
Signal: Pending
Market Profile
Signal: Pending
Market Cap
25.3M
Enterprise Value
37.0M
Public Float
53.6
Broker Target
29
Shares Out
259.2M
Long Interest
92
Short Interest
8
Exchange
LSE
Currency Code
GBX
ISIN
GB00BF33H870
Market
LSE - AIM
Sector
Pharmaceuticals and Biotechnology
Float / Shares Ratio
-
Short vs Long Delta
-
EV / Market Cap
-

Financials Matrix

News And Alerts First

1 live alert now opens the financials desk for SBTX.

Start with the headline flow and alert tape first. Then drop straight into Financial Forecastist below for the revenue path, EPS shape, cash pressure and balance-sheet read while the catalyst context is still hot.
Live Alerts Data 2025-12-05 Forecastist Below
Read the alert tape first, then move into Financial Forecastist below. Use AI Expand on any catalyst card to open the AI explanation and results tables without losing the ticker context.
1 Alerts
Front Of Desk
SkinBioTherapeutics PLC has fresh filing flow live now, so the tape is framing the revenue, leverage and valuation story below.
Overall Stability
Signal: Pending
Profitability
Signal: Pending
Debt & Cash
Signal: Pending
Valuation Risk
Signal: Pending
Forward Expectation
Signal: Pending
Dividend Safety
Signal: Pending
Divi Rate
-
Ex Divi
-
Earnings Date
2026-03-24
Net Debt
-3.8M
Cash
4.8M
EPS
-
Net Income
-696.3K
Revenue
4.6M
Enterprise Value
37.0M
Trailing PE
-
Forward PE
-
Price Sales TTM
5.4481
Price Book MRQ
2.6827
EV Revenue
4.6318
EV EBITDA
-8.0802
Financial Forecastist

Mixed financial engine

Revenue is accelerating +5459.3% against the prior comparable period. Net margin is expanding by 2,825.8 pts. Net debt is building +212.6%.

Revenue +5459.3% Net Income -121.8% FCF -72.1% Current Ratio 4.84x Forward Rev 0
Mixed
Quarter Revenue
3.1M
+5459.3%
vs prior comparable quarter
Net Margin
+11.0%
+2825.8 pts
profitability pulse
Free Cash Flow
-498.5K
-72.1%
cash conversion
Net Debt / EBITDA
-5.8x
+212.6%
lower is cleaner
Revenue Engine

Latest quarter printed 3.1M with the top line pushing higher against the last comparable period.

Profit Stack

Net income landed at 337.8K and the margin profile is broadening. That usually tells us whether operating leverage is finally kicking in.

Balance-Sheet Pressure

Cash sits near 4.8M while net debt is -3.8M. The leverage stack is moving the wrong way.

Quarterly Revenue Runway

Actual revenue bars, consensus revenue where available, plus the terminal model path.

Profit And Cash Conversion

Net income and free cash flow moving together is usually what separates genuine improvement from noise.

Balance-Sheet Pressure

Cash, net debt and liquidity tell us whether the business is strengthening or just surviving.

Annual Power Curve

Longer-cycle revenue and net income help frame whether the company is compounding or rolling over.
Q4 2023
Consensus
0
Revenue Path
0.00
EPS / Earnings
Growth cue -
Q1 2024
Consensus
0
Revenue Path
0.00
EPS / Earnings
Growth cue -
Q3 2024
Consensus
0
Revenue Path
0.00
EPS / Earnings
Growth cue -
Q4 2024
Consensus
0
Revenue Path
0.00
EPS / Earnings
Growth cue -
FY 2026
Consensus
6.2M
Revenue Path
0.00
EPS / Earnings
Growth cue +1.0%
FY 2027
Consensus
8.2M
Revenue Path
0.00
EPS / Earnings
Growth cue +95.5%

Quarterly Statement Tape

Last 6 Quarters
Period Revenue Net Income FCF Net Debt
Q2 2025 3.1M 337.8K -498.5K -3.8M
Q4 2024 1.6M -1.0M -805.9K -210.5K
Q2 2024 1.1M -1.5M -1.4M 17.8K
Q4 2023 106.6K -1.3M -1.4M -2.7M
Q2 2023 55.1K -1.6M -1.8M -1.2M
Q4 2022 77.0K -1.3M -1.0M -656.5K

Annual Financial Power

Last 5 Years
Period Revenue Net Income EBITDA FCF
FY 2025 4.6M -696.3K -196.5K -1.3M
FY 2024 1.2M -2.9M -2.7M -2.9M
FY 2023 132.1K -2.8M -3.0M -2.8M
FY 2022 74.8K -2.8M -3.0M -2.8M
FY 2021 0 -1.4M -1.5M -1.7M

Structure DNA

Market Structure DNA

Balanced Structure profile with trend mixed

Price is 21.1% through the 52-week range, +28.1% vs 50DMA and -30.4% vs 200DMA. 53.2% of the register is locked by institutions and insiders, leaving 46.8% free float. Capital rhythm reads no cadence with forward yield near 0.0% and payout around 0.0%.

Trend mixed Institutional gravity Moderate income rhythm As Of 2026-04-19
Balanced Structure
Structure Score
49.1 / 100
Balanced Structure
Trend Stack
+28.1% / -30.4%
vs 50DMA / 200DMA
52W Position
21.1%
auction position inside the yearly range
Ownership Lock
53.2%
14.3% institutions | 38.8% insiders
Pressure Pocket
46.8% free float
Vendor short-float fields were not supplied
Capital Rhythm
No cadence
Yield 0.0% | payout 0.0%
Trend Runway

Implied spot is 9.75 with the stock +28.1% vs 50DMA and -30.4% vs 200DMA. The tape is sitting 21.1% through the 52-week range, which frames the regime as trend mixed.

Ownership Register

Institutions hold about 14.3% and insiders about 38.8%, locking roughly 53.2% of the register and leaving 46.8% in free float. That reads as institutional gravity.

Pressure Pocket

The API did not return a usable short-float field for this ticker, so the pressure score leans more on float lock and crowding than a full short ledger.

Capital Rhythm

Dividend cadence reads no cadence with - event(s) in the last full year, a five-year average of -, and stability score 0.0/100. Forward yield sits near 0.0% while payout is around 0.0%.

Structure Score

One-glance gauge for the current market-structure regime.

Pillar Radar

Trend, ownership, pressure, and capital rhythm mapped on one wheel.

Position And Float Balance

Shows whether the stock is extended, tightly held, or carrying capital-return support.

Dividend Cadence Tape

Historical dividend-event counts help reveal how dependable the income rhythm has been.

Dividend Cadence Ledger

No cadence
Year Dividend Count Context
Dividend history has not been normalized yet.

Structure Facts

Live Snapshot
Implied Spot
9.75
derived from market cap / shares
52W High
27.50
upper auction edge
52W Low
5.00
lower auction edge
Beta
0.20
volatility character
Shares Out
259.2M
fully diluted count
Shares Float
138.9M
tradable register
Shares Short
0
borrowed stock
Short Ratio
0.0x
days-to-cover style read
Ex-Dividend
-
next ex-date not supplied
Dividend Pay
-
payment date not supplied
Last Split
-
split date not supplied

Capital Radar

Capital Regime
—
Building signal blend...
Smart Money Tilt
—
Public vs institutions
Target Conviction
—
Broker coverage pulse
Insider Pressure
—
Director + TR1 flow
Last Held Position
-
Public Hands
-
Institutions
28.57
Institutions As Of
2026-01-15
Avg Broker Target
-
Upside Vs Price
-
Purchase Director Dealing
0
Sale Director Dealing
0
Purchase TR1
15
Sale TR1
8
Broker Coverage Rows
0
Institution Holders Tracked
5
Public Vs Institutional Ownership (3D)
Top Institution Holders (Latest Per Holder)
Director Dealing Sentiment Flow
Broker Target Bias
Signal: Pending
Capital Momentum Matrix
Broker Targets Vs Price
Aggregated Institution Weight By Holder

Short Data - Last 30 Days

Nexus Pulse Engine

Overall Buy/Sell/Hold
Signal: Pending
Technical Composite
Signal: Pending
Financial Composite
Signal: Pending
Fundamental Composite
Signal: Pending
Short Pressure
Signal: Pending
Momentum Bias
Signal: Pending

Volatility Lab

ATR(14)
Realized Vol (20d)
Volume Spike Z

AI Charts

News And Alerts First

The alert tape opens the door for SBTX, and AI Charts sits just below.

Start with the headline flow and live catalyst tape first. Then move straight into AI Charts below for price reaction, AI targets, chart structure and catalyst beacons while the news context is still hot.
Live Tape Data 2025-12-05 AI Charts Below
Read the alert tape first, then move into AI Charts below. Use AI Expand on any catalyst card to open the AI explanation and results tables instantly.
1 Today
Catalyst Pulse
SkinBioTherapeutics PLC has fresh news flow live now, so the tape is framing the chart workspace below.
AI Charts Studio
SBTX Price History
Live structure, automated forecasts, technical overlays and catalyst beacons in one chart workspace.
30 Day View Window 30D Data 2025-12-05 Open Preview Studio Brief
Chart Intelligence Suite
Swipe the timeframe, call the overlays, and keep the AI signal stack fused into one chart cockpit.
The mobile chart console is now framed as one connected surface so forecasting, structure, catalyst beacons and chart tools all sit inside the price workspace.

Automated signalling scans momentum shifts, crossovers and volatility breaks in real time. Automated AI forecasts map best, average and worst simulation paths forward, predictive MACD extends the momentum story, and catalyst beacons pin market-moving headlines directly onto price action so users can connect news, signals and structure without leaving the chart.

Automated Signalling Automated AI Forecasts Predictive MACD Catalyst Beacons Live Price Structure
Desk Snapshot Member Login
Indicators0
Technicals0
AI Forecast 32.91%
RSI Gauge
Price Change
AI Forecast